[Case report: RAEB in a patient with rheumatoid arthritis treated with methotrexate and infliximab].
Anti TNF-alpha drugs seem to be the new frontier of Rheumatoid Arthritis (RA) therapy. The association infliximab methotrexate has been approved for the treatment of RA not responding to the classic therapy, but the short clinical experience in using antiTNF-alpha molecules brings to segnalation of new risks or adverse events. We describe a case of a patient, treated for many years with classic RA therapy, which developed a refractory anemia after treatment with association infliximab-methotrexate.
D'Alessandro
Giuseppe
G
II Medicina Interna Universitaria, Azienda Ospedaliero Universitaria Ospedali Riuniti, 71100 Foggia. meduni@unifg.it
Bianco
Maria Rosaria
MR
Politis
Spiridion
S
Ferrandina
Celestino
C
Rossi
Giuseppe
G
Altomare
Emanuele
E
D000754:Anemia, Refractory, with Excess of Blasts / Q000097:blood / Q000139:chemically induced*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D044963:Biopsy, Fine-Needle; D001853:Bone Marrow / Q000473:pathology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000069285:Infliximab; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D008727:Methotrexate